ErnieBilco
2 years ago
On April 8, 2021, Kaleido Biosciences, Inc. (the “Company”) delivered formal notice to The Nasdaq Stock Market, Inc. that the Company intends to
voluntarily delist its common stock, par value $0.001 per share (the “Common Stock”), from the Nasdaq Global Select Stock Market (“Nasdaq”) in
connection with the Company’s cessation of all operations
whytestocks
4 years ago
Just In: $KLDO Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer
LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, announced that Daniel Menichella has been appointed Presi...
Find out more KLDO - Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer
whytestocks
5 years ago
News: $KLDO Kaleido Biosciences Announces Presentation of Clinical Study and Ex Vivo Data Supporting the Development of Novel Microbiome Metabolic Therapies for Hyperammonemia at The International Liver Congress(TM) 2019 (EASL)
LEXINGTON, Mass., April 12, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today presen...
In case you are interested https://marketwirenews.com/news-releases/kaleido-biosciences-announces-presentation-of-clinical-study-and-ex-vivo-data-supporting-the-development-of-novel-microbiome-metabolic-therapies-for-hyperammonemia-at-the-international-liver-congress-tm-2019-easl--7990462.html